Brian Tanquilut

In a report published Tuesday, Jefferies analyst Brian Tanquilut reiterated a Buy rating on Mednax (NYSE: MD), and raised the price target from $95.00 to $108.00. In the report, Jefferies noted, “We continue to have a very positive bias on MD and view the stock's recent plateauing as a...

In a report published on Tuesday, Jefferies analyst Brian Tanquilut initated coverage on BioScrip (NASDAQ: BIOS) with a Buy Rating and a $17.00 price target. In the report, Jefferies pointed out, "Our positive view on BIOS is driven primarily by our expectation for sustained, robust top line...

IPC The Hospitalist Co. (NASDAQ: IPCM) filed an 8-K yesterday, reporting it was subpoenaed by the US Attorney's Office for the Northern District of Illinois. Jefferies analysts Arthur Henderson, Brian Tanquilut, and Paxton Scott believe this is routine for companies who derive a substantial amount...

Jefferies & Company analysts Arthur I. Henderson, Brian Tanquilut, and Paxton Scott have upgraded IPC The Hospitalist Co. (NASDAQ: IPCM) to Buy. The analysts believe IPCM has been oversold, and is now valued too low relative to its growth rate. They expect "volumes to pick up in 2H10 as recent...

Jefferies & Company analysts Arthur I. Henderson, Paxton Scott and Brian Tanquilut rated shares of Sun Healthcare Group Inc (Nasdaq: SUNH) a Buy, with a price target of $11 per share. The analysts said that Sun Healthcare Group Inc has decided to split itself into two companies, one of them a...